Literature DB >> 16705512

[Corneal and conjunctival findings in systemic silver intoxication].

W Flögel1, S Widmeier, P Hotz, L Schärer, D Barthelmes, K Landau, M A Thiel.   

Abstract

BACKGROUND: Chronic silver intoxication is a rare disease and therefore the typical ocular findings may be missed. Based on a case with severe intoxication, the clinical and histological findings as well as the prognosis in argyria are presented. HISTORY: A 33-years-old-employee of a battery production plant developed a biopsy proven systemic argyria. On slit lamp examination the conjunctiva showed a dark, blue-grey discoloration in the areas of the tear flow and the small conjunctival arteries. Diffuse silver deposits were noticed on the level of Descemet's membrane without endothelial damage. Silver deposits were also visible in the trabecular meshwork. Chemical reaction of the silver particles upon exposure to UV light results in irreversible tissue discoloration. Without options for an effective treatment, early diagnosis and prevention of overexposure are most important.
CONCLUSIONS: The typical ocular findings in systemic argyria are helpful in occupational medicine for establishing the correct diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705512     DOI: 10.1055/s-2006-926556

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  3 in total

1.  [Ocular argyria after long-term application of eyelash and eyebrow tints].

Authors:  Marlene Saßmannshausen; Martina C Herwig-Carl; Frank G Holz; Karin U Loeffler
Journal:  Ophthalmologie       Date:  2021-09-17

2.  Diagnostic methods in ocular argyrosis: case report.

Authors:  Monika Sarnat-Kucharczyk; Dorota Pojda-Wilczek; Ewa Mrukwa-Kominek
Journal:  Doc Ophthalmol       Date:  2016-07-08       Impact factor: 2.379

Review 3.  Clinical and Forensic Aspects of the Different Subtypes of Argyria.

Authors:  Luís Mota; Ricardo Jorge Dinis-Oliveira
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.